Impact BioMedical, INC. Professional Fees
Impact BioMedical, INC. (IBO) reported Professional Fees of $92.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProfessionalFees · last filed 2026-08-07
- Impact BioMedical, INC. professional fees for the quarter ending 2026-06-30 was $92.00K, a 77.62% decline year-over-year.
- Impact BioMedical, INC. professional fees for the quarter ending 2026-03-31 was $258.00K, a 15.70% increase year-over-year.
- Impact BioMedical, INC. professional fees for the quarter ending 2025-12-31 was $137.00K, a 3.01% increase year-over-year.
- Impact BioMedical, INC. professional fees for the quarter ending 2025-09-30 was $234.00K, a 91.80% increase year-over-year.
- Impact BioMedical, INC. professional fees for fiscal 2025 was $1.00M, a 125.34% increase from fiscal 2024.
- Impact BioMedical, INC. professional fees for fiscal 2024 was $446.00K, a 38.40% decline from fiscal 2023.
- Impact BioMedical, INC. professional fees for fiscal 2023 was $724.00K, a 0.28% increase from fiscal 2022.
- Impact BioMedical, INC. professional fees for fiscal 2022 was $722.00K.
| Period end | Professional Fees 3 month | Professional Fees 3 month as first filed | Professional Fees 6 month | Professional Fees 6 month as first filed | Professional Fees 9 month | Professional Fees 9 month as first filed | Professional Fees 12 month | Professional Fees 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $92.00K 10-Q · filed 2026-08-07 | $350.00K 10-Q · filed 2026-08-07 | $487.00K derived: sum of 3 quarters · filed 2026-08-07 | $721.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $258.00K 10-Q · filed 2026-05-12 | $395.00K derived: sum of 2 quarters · filed 2026-05-12 | $629.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.04M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $371.00K derived: sum of 2 quarters · filed 2026-03-11 | $782.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.00M 10-K · filed 2026-03-11 | ||||
| 2025-09-30 | $234.00K 10-Q · filed 2025-11-07 | $645.00K derived: sum of 2 quarters · filed 2026-08-07 | $868.00K 10-Q · filed 2025-11-07 | $1.00M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $411.00K 10-Q · filed 2026-08-07 | $634.00K 10-Q · filed 2026-08-07 | $767.00K derived: sum of 3 quarters · filed 2026-08-07 | $889.00K derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $223.00K 10-Q · filed 2026-05-12 | $356.00K derived: sum of 2 quarters · filed 2026-05-12 | $478.00K derived: sum of 3 quarters · filed 2026-05-12 | $524.00K derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $255.00K derived: sum of 2 quarters · filed 2026-03-11 | $301.00K derived: sum of 3 quarters · filed 2026-03-11 | $446.00K 10-K · filed 2026-03-11 | ||||
| 2024-09-30 | $122.00K 10-Q · filed 2025-11-07 | $168.00K derived: sum of 2 quarters · filed 2025-11-07 | $313.00K 10-Q · filed 2025-11-07 | $287.00K derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | $46.00K 10-Q · filed 2025-08-14 | $167.00K 10-Q · filed 2024-08-13 | $191.00K 10-Q · filed 2025-08-14 | $445.00K 10-Q · filed 2024-08-13 | $165.00K derived: sum of 3 quarters · filed 2025-08-14 | $482.00K derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $145.00K 10-Q · filed 2025-05-14 | $278.00K 10-Q · filed 2024-05-10 | $119.00K derived: sum of 2 quarters · filed 2025-05-14 | $436.00K derived: sum of 3 quarters · filed 2025-05-14 | $843.00K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $291.00K derived: sum of 2 quarters · filed 2025-03-28 | $698.00K derived: sum of 3 quarters · filed 2025-03-28 | $724.00K 10-K · filed 2025-03-28 | $1.26M 10-K · filed 2024-02-20 | |||
| 2023-09-30 | $317.00K 10-Q · filed 2024-11-12 | $435.00K 10-Q · filed 2023-11-13 | $724.00K derived: sum of 2 quarters · filed 2024-11-12 | $750.00K 10-Q · filed 2024-11-12 | $1.12M 10-Q · filed 2023-11-13 | $1.17M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $407.00K 10-Q · filed 2024-08-13 | $686.00K 10-Q · filed 2024-08-13 | $852.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.03M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $280.00K 10-Q · filed 2024-05-10 | $445.00K derived: sum of 2 quarters · filed 2024-05-10 | $628.00K derived: sum of 3 quarters · filed 2024-05-10 | $857.00K derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $348.00K derived: sum of 2 quarters · filed 2024-02-20 | $577.00K derived: sum of 3 quarters · filed 2024-02-20 | $722.00K 10-K · filed 2024-02-20 | ||||
| 2022-09-30 | $183.00K 10-Q · filed 2023-11-13 | $412.00K derived: sum of 2 quarters · filed 2023-11-13 | $557.00K 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | $229.00K 10-Q · filed 2023-10-05 | $356.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |